China Education Equipment Purchasing Network News: Hyperthyroidism is a common immune disease with an incidence rate of about 1% in China and an estimated 13 million patients. However, the current treatment of hyperthyroidism is not ideal, and complications often endanger the lives of patients. A new research result recently discovered a new mechanism for the treatment of hyperthyroidism, which will help doctors predict the occurrence of hyperthyroidism earlier.
The research team co-chaired by Prof. Song Huaidong from the State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, and Prof. Huang Wei from the National Center for Human Genome Research, used disease-related samples accumulated over the years and used genome-wide association analysis With the most advanced genomic technology, the study found two new hyperthyroidism susceptibility sites, and believed that patients with hyperthyroidism may have two different pathogenesis. The research results have been published in the latest issue of "Nature Â· Genetics".
The research team analyzed hundreds of thousands of sites in the variation map of the entire genome, compared the differences between patients and normal people, found possible sites of disease, and performed sample and functional verification. In addition to confirming the four susceptible sites related to hyperthyroidism, this study also found two new susceptible sites for hyperthyroidism, thus identifying two related genes, one of which has not been reported before, the research team Name it "GDCG4p14". These two genes will affect the function of T cells that regulate immunity, so it may be a newly recognized susceptibility gene for hyperthyroidism.
At the same time, the researchers found that there may be two different pathogenesis mechanisms in patients with hyperthyroidism. After treatment of hyperthyroidism, thyroid stimulating hormone receptor antibody (TRAb) continues to be positive, which is an important predictor of relapse after drug withdrawal. In the clinical treatment of hyperthyroidism, the TRAb antibody has a low conversion rate, and the continued positive TRAb antibody will lead to recurrence of hyperthyroidism, which is why the hyperthyroidism cannot be cured for a long time. The research team found that after drug treatment, the polymorphism of the thyroid stimulating hormone receptor gene was not related to patients with negative TRAb antibodies, but was closely related to patients who continued to be positive.
This discovery provides a valuable means for clinical treatment, is used to more accurately distinguish two types of patients in the clinic, and helps to guide the clinical use of hyperthyroidism, and provides effective pre-judgment for the cure of patients.
Hang Tag,Printing Label,Cardboard Boxes,Paper Bags Manufacturer and Supplier.
Xing Hua Printing Factory , https://www.xinghuaprint.com